![]() |
市場調查報告書
商品編碼
1485253
上游生物加工市場 - 按產品、使用方式、方式、應用、最終用戶 - 全球預測,2024 年 - 2032 年Upstream Bioprocessing Market - By Product, Usage Mode, Mode, Application, End-user - Global Forecast, 2024 - 2032 |
上游生物加工市場規模預計從 2024 年到 2032 年將以 9.7% 的複合年成長率擴大。隨著對有效治療的需求不斷增加,慢性病的盛行率不斷上升,從而促進了生物製劑的生產,並為生物加工技術的更廣泛採用鋪平了道路。
政府對生物技術研發的有利舉措和投資的湧入正在推動上游生物加工產業的創新。舉個例子,2023年9月,Sartorius和Repligen公司推出了整合式生物反應器系統,將前者的Biostat攪拌槽反應器(STR)與Repligen的XCell交替切向流(ATF)技術結合。
製藥公司合約製造組織 (CMO) 的擴張和生物加工活動的外包也增加了上游生物加工的採用。此外,細胞培養技術和一次性生物反應器的技術創新正在提高效率和可擴展性,進一步推動產業成長。
上游生物加工市場分為產品、使用方式、方式、應用、最終用戶和地區。
在產品方面,預計2024年至2032年間細胞培養產品領域的市場價值將以12.5%的成長率成長。細胞培養技術的重大進步(例如一次性生物反應器)正在提高效率和可擴展性。生物技術和製藥行業的擴張也將增加對細胞培養產品的需求。
在應用方面,到2032年,疫苗生產領域的上游生物加工產業將以複合年成長率10.8%的速度擴張。生物技術的進步正在促進新型候選疫苗的開發,並增加了對上游生物加工技術的吸引力。政府為疫苗研發提供資金將進一步有利於該領域的成長。
從地區來看,由於政府和私人組織對生技研發的投資不斷增加,亞太地區上游生物加工市場在2024年至2032年期間的複合年成長率將達到12.1%。慢性病的日益普及刺激了對生物製藥的需求,並推動了對上游生物加工解決方案的需求。大量熟練勞動力的存在和較低的製造成本正在吸引生物技術公司,進一步推動區域產業的發展。
Upstream Bioprocessing Market size is projected to expand at 9.7% CAGR from 2024 to 2032. Rapid advancements in biotechnology and genetic engineering are driving the development of novel biopharmaceuticals, subsequently accelerating the demand for upstream bioprocessing solutions. The growing prevalence of chronic diseases along the rising need for effective treatments is boosting the production of biologics and making way for the higher adoption of bioprocessing technologies.
The influx of favorable government initiatives and investments in biotechnology R&D is driving innovations in the upstream bioprocessing industry. To cite an instance, in September 2023, Sartorius and Repligen Corporation introduced an integrated bioreactor system, combining the former's Biostat Stirred-Tank Reactor (STR) with Repligen's XCell Alternating Tangential Flow (ATF) technology.
The expansion of contract manufacturing organizations (CMOs) and outsourcing of bioprocessing activities by pharmaceutical companies is also increasing the adoption of upstream bioprocessing. Moreover, technological innovations in cell culture techniques and single-use bioreactors are leading to enhanced efficiency and scalability, further driving the industry growth.
The upstream bioprocessing market is segregated into product, usage mode, mode, application, end-user, and region.
In terms of product, the market value from the cell culture products segment is anticipated to rise at 12.5% growth rate between 2024 and 2032. The increasing demand for biopharmaceuticals is fueling the need for cell culture products for protein expression and production. Significant advancements in cell culture techniques, like single-use bioreactors are improving efficiency and scalability. The expansion of biotechnology and pharmaceutical sector will also boost the demand for cell culture products.
With respect to application, the upstream bioprocessing industry from the vaccine production segment will expand at 10.8% CAGR until 2032. The rising global demand for vaccines to combat infectious diseases is driving the need for efficient bioprocessing solutions. The advancements in biotechnology are facilitating the development of novel vaccine candidates and increasing the appeal for upstream bioprocessing technologies. The rollout of government funding for vaccine R&D will further benefit the segment growth.
Regionally, the Asia Pacific upstream bioprocessing market will record 12.1% CAGR between 2024 and 2032, on account of the increasing investments in biotechnology R&D by government and private organizations. The growing prevalence of chronic diseases is fueling the demand for biopharmaceuticals and driving the need for upstream bioprocessing solutions. The presence of a large pool of skilled labor and lower manufacturing costs are attracting biotechnology companies, further driving the regional industry progression.